Ariaee Nazila, Yadegari Yaser, Shabestari Mohamad, Asili Javad, Panahi Maryam, Ghorbani Jalal, Jabbari Farahzad
Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Preventive Cardiovascular Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Clin Mol Allergy. 2022 Feb 10;20(1):3. doi: 10.1186/s12948-022-00169-w.
Allergic rhinitis is a widespread disorder across the globe. The Shirazi thyme (Zataria multiflora) has been shown to have considerable antioxidant and anti-inflammatory properties. This study assessed the effect of this herbal product on alterations in inflammatory/anti-inflammatory cytokines.
This study was conducted on the bank sample before and after the intervention to measure interleukin-4, interleukin-5, and interferon -γ levels with the ELISA test method in a supernatant taken from the PBMC cell culture from 30 allergic rhinitis patients.
The IL-4 level had no significant difference between the two groups before the treatment. However, it had a significant increase in the case group after the treatment. The IL-5 level was significantly higher in the case group before the treatment. Nevertheless, there were no significant differences between the case and control groups after the treatment. Similarly, no significant differences were observed between the two groups considering IFN-γ before and after the treatment.
Consuming thyme with an increase in anti-inflammatory cytokine IL-4 and a decrease in IL-5 cytokine control inflammation and improvement in allergic rhinitis symptoms. Clinical trial details This clinical trial study was recorded at 22.5.2014 in the Iran Registry of Clinical Trials code: (IRCT2016121823235N6) https://www.irct.ir/trial/19852.
变应性鼻炎是一种全球范围内广泛存在的疾病。伊朗百里香（Zataria multiflora）已被证明具有相当的抗氧化和抗炎特性。本研究评估了这种草药产品对炎性/抗炎细胞因子变化的影响。
本研究在干预前后对30例变应性鼻炎患者外周血单个核细胞（PBMC）细胞培养上清液采用酶联免疫吸附测定（ELISA）试验方法测量白细胞介素-4、白细胞介素-5和干扰素-γ水平。
治疗前两组间白细胞介素-4水平无显著差异。然而，治疗后病例组白细胞介素-4水平显著升高。治疗前病例组白细胞介素-5水平显著更高。然而，治疗后病例组与对照组之间无显著差异。同样，治疗前后两组间干扰素-γ水平无显著差异。
食用百里香可使抗炎细胞因子白细胞介素-4增加，白细胞介素-5细胞因子减少，从而控制炎症并改善变应性鼻炎症状。临床试验详情 本临床试验研究于2014年5月22日在伊朗临床试验注册中心注册，注册号：（IRCT2016121823235N6）https://www.irct.ir/trial/19852 。
